title: Doxapram and developmental delay at 12 months in children born extremely preterm.
abstract: OBJECTIVE
  To examine the relation of doxapram to a developmental score achieved by a structured telephone interview in a group of extremely-preterm-born children.
  
  
  METHODS
  Parents of 88 children born extremely preterm were contacted by telephone and interviewed by a structured questionnaire (R-PDQ) when the corrected age of their child was 9-15 mo.
  
  
  RESULTS
  We found that doxapram treatment was associated with a deficit in age-adjusted R-PDQ score.
  
  
  CONCLUSIONS
  Doxapram may have a negative effect on neurodevelopmental outcome.
authors.affiliation: Department of Neonatology, The Juliane Marie Centre, Copenhagen University Hospital, Copenhagen, Denmark. alando@dadlnet.dk
authors.forename: Ane
authors.initials: A
authors.lastname: Lando
authors.forename: Anja
authors.initials: A
authors.lastname: Klamer
authors.forename: Finn
authors.initials: F
authors.lastname: Jonsbo
authors.forename: Janne
authors.initials: J
authors.lastname: Weiss
authors.forename: Gorm
authors.initials: G
authors.lastname: Greisen
mesh_terms: D016022:Case-Control Studies; D002658:Developmental Disabilities / Q000139:chemically induced*; D004315:Doxapram / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D019102:Infant, Very Low Birth Weight; D016014:Linear Models; D008297:Male; D019141:Respiratory System Agents / Q000009:adverse effects*
chemical_list: D019141:Respiratory System Agents; D004315:Doxapram